Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
opioid medication
|
| gptkbp:activeDuring |
oxymorphone
|
| gptkbp:brand |
gptkb:Opana_IR
Opana ER |
| gptkbp:chemicalFormula |
C17H19NO4
|
| gptkbp:compatibleWith |
10-30%
|
| gptkbp:contraindication |
addiction
tolerance overdose respiratory depression |
| gptkbp:formulation |
extended-release
immediate-release |
| https://www.w3.org/2000/01/rdf-schema#label |
Opana
|
| gptkbp:isATypeOf |
357-57-2
|
| gptkbp:lastProduced |
2006
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Endo_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:United_States |
| gptkbp:notableFeature |
gptkb:Hydromorphone
Oxycodone |
| gptkbp:operates_in |
N02AA06
|
| gptkbp:providesSupportFor |
II
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
nausea drowsiness constipation |
| gptkbp:symptoms |
anxiety
muscle pain insomnia |
| gptkbp:usedFor |
pain relief
|